Therefore, combining TRAIL administration with standard chemo- or radiotherapy may prove more efficacious than administering TRAIL alone, as suggested by promising results in pre-clinical models of glioma, renal cell carcinoma, breast, prostate, and bladder cancer [55-59]. This evidence concerns the gene TNFSF10 and glioma.